시장보고서
상품코드
1422079

분자 표적 진단 시장 : 제품 및 서비스, 샘플 유형, 검사 유형, 기술, 용도, 최종사용자, 지역별, 기회 및 예측(2017-2031년)

Molecular Targeted Diagnostics Market Assessment, By Product & Service, By Sample Type, By Test Type, By Technology, By Application, End-user, By Region, Opportunities and Forecast, 2017-2031F

발행일: | 리서치사: Market Xcel - Markets and Data | 페이지 정보: 영문 211 Pages | 배송안내 : 3-5일 (영업일 기준)


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

세계 분자 표적 진단 시장 규모는 2023년 147억 5,000만 달러에서 예측 기간 동안 7.07%의 CAGR로 2031년에는 254억 7,000만 달러에 달할 것으로 예상됩니다. 세계 분자 표적 진단 시장의 성장과 진화는 동반 진단에 대한 수요 증가, 기술 발전, 만성 질환의 급증, 개인 맞춤형 의료의 출현, 정부 이니셔티브, R&D 투자 증가 등의 요인에 의해 촉진되고 있습니다. 주요 촉진요인 중 하나는 동반진단약에 대한 수요 증가입니다. 동반진단은 치료 효과를 예측하는 데 도움이 되는 특정 바이오마커를 식별하여 환자 개개인에게 맞춤화된 치료를 제공하는 데 중요한 역할을 합니다. 또한, 기술의 지속적인 발전으로 정확도와 정밀도가 향상된 첨단 진단 도구가 개발되어 분자 표적 진단 시장의 성장을 촉진하고 있습니다. 암, 심혈관 질환, 감염성 질환을 포함한 만성 질환의 유병률이 증가함에 따라 신뢰할 수 있는 진단 기술의 필요성이 증가하고 있습니다. 또한, 개인 맞춤형 의료의 등장은 개인의 유전적 체질과 특정 바이오마커에 맞는 치료를 강조함으로써 헬스케어에 혁명을 일으키고 있습니다.

개인화 의료의 등장

개별화 의료의 등장은 분자 표적 진단 시장을 이끄는 중요한 요인입니다. 이 접근법은 환자별 유전자 프로필, 바이오마커, 특징에 따라 치료를 조정하는 것입니다. 분자 표적 진단과 같은 정밀 진단 도구는 치료 전략을 결정하는 중요한 특정 유전자 변화와 바이오마커를 식별하는 데 중요합니다. 이러한 진단 도구는 표적 치료를 안내하고, 치료 결과를 예측하고, 환자의 반응을 향상시키는 데 중요한 역할을 합니다.

R&D 투자 증가

진단 기술의 기술 개발은 R&D 자금의 증가로 인해 촉진되고 있습니다. 이러한 재정적 투자는 보다 정확하고 효율적이며 광범위하게 사용할 수 있는 진단 도구를 개발하는 데 도움이 되고 있습니다. 또한, 복잡한 진단 검사의 검증 및 승인에도 도움이 되고 있으며, 다양한 의료 분야에서 활용도가 높아지고 있습니다. 이러한 자금 조달의 증가는 진단의 정확성과 유효성을 향상시키고 궁극적으로 더 넓은 범위의 환자 치료를 개선함으로써 시장 확대에 크게 기여하고 있습니다.

세계 분자 표적 진단 시장을 조사했으며, 시장 정의와 개요, 시장 규모 추이 및 예측, 각종 부문별·지역별 상세 분석, 산업 구조, 시장 성장에 영향을 미치는 요인 분석, 사례 연구, 경쟁 상황, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 조사 방법

제2장 프로젝트 범위와 정의

제3장 세계의 분자 표적 진단 시장 전망

제4장 주요 요약

제5장 세계의 분자 표적 진단 시장 전망

  • 시장 규모와 예측
  • 제품별
    • 시약·키트
    • 기기
    • 서비스·소프트웨어
  • 샘플 유형별
    • 혈액, 혈청, 혈장
    • 소변
    • 기타
  • 테스트 유형별
    • 임상 검사
    • PoC 테스트
  • 기술별
    • 등온 핵산 증폭 기술
    • DNA 시퀀싱과 차세대 시퀀싱
    • PCR
    • ISH(In Situ Hybridization)
    • DNA 마이크로어레이
    • 차세대 시퀀싱
    • 기타
  • 용도별
    • 감염증 진단
    • 종양 검사
    • 유전자 검사
    • 혈액 검사
    • 기타
  • 최종사용자별
    • 병원·클리닉
    • 진단 실험실
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 남미
    • 아시아태평양
    • 중동 및 아프리카
  • 기업별 시장 점유율

제6장 세계의 분자 표적 진단 시장 전망 : 지역별

  • 북미
  • 유럽
  • 남미
  • 아시아 태평
  • 중동 및 아프리카

제7장 시장 매핑

  • 제품별
  • 샘플 유형별
  • 검사 유형별
  • 기술별
  • 용도별
  • 최종사용자별
  • 지역별

제8장 거시적 환경과 산업 구조

  • 수급 분석
  • 수출입 분석
  • 밸류체인 분석
  • PESTEL 분석
  • Porter's Five Forces 분석

제9장 시장 역학

  • 성장 추진요인
  • 성장 억제요인(과제·장벽)

제10장 규제 프레임워크·혁신

  • 임상시험
  • 특허 상황
  • 규제 당국 승인
  • 혁신/최신 기술

제11장 주요 기업 상황

  • 시장 리더 상위 5개사 경쟁 매트릭스
  • 시장 리더 상위 5개사 시장 매출 분석
  • M&A·합작투자(해당되는 경우)
  • SWOT 분석(참여 5개사)
  • 특허 분석(해당되는 경우)

제12장 가격 분석

제13장 사례 연구

제14장 주요 기업 전망

  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Abbott Laboratories
  • Becton, Dickinson, and Company
  • Siemens Healthineers
  • Agilent Technologies, Inc.
  • Hologic, Inc.
  • bioMerieux SA
  • QIAGEN Biotechnology Malaysia Sdn Bhd.
  • Danaher Corporation
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.

제15장 전략적 제안

제16장 당사 소개와 면책사항

ksm 24.02.19

Global molecular targeted diagnostics Market size was valued at USD 14.75 billion in 2023 which is expected to reach USD 25.47 billion in 2031 with a CAGR of 7.07% for the forecast period between 2024 and 2031. Various factors propel the growth and evolution of the global molecular targeted diagnostics market. Some of the drivers are growing need for companion diagnostics, advancements in technology, a surge in prevalence of chronic diseases, the emergence of personalized medicine, governmental initiatives, and increasing investment in research & development. One of the key drivers of global molecular targeted diagnostics market is the increasing demand for companion diagnostics, which plays a crucial role in tailoring treatments to individual patients by identifying specific biomarkers that assist in predicting treatment responses. Moreover, continuous advancements in technology have led to the development of advanced diagnostic tools that offer enhanced accuracy and precision, fostering the expansion of global molecular targeted diagnostics market. The increasing prevalence of chronic diseases including cancer, cardiovascular diseases, and infectious ailments, has amplified the necessity for reliable diagnostic techniques. Furthermore, the emergence of personalized medicine has revolutionized healthcare by emphasizing treatments tailored to an individual's genetic makeup and specific biomarkers.

Government initiatives supporting precision medicine and healthcare infrastructure expansion, coupled with increasing awareness and patient empowerment regarding the benefits of early diagnosis and targeted treatments, have significantly propelled the adoption of molecular targeted diagnostics. Additionally, significant investments in research and development by pharmaceutical and biotech companies aim to innovate and improve diagnostic tools, fostering growth in global molecular targeted diagnostics market by enhancing accuracy, efficacy, and accessibility.

Advent of Personalized Medicine

The emergence of personalized medicine is a pivotal driver propelling the global molecular targeted diagnostics market. This approach tailors' treatments according to patients' unique genetic profiles, biomarkers, and characteristics. Precision diagnostic tools, like molecular targeted diagnostics, are important for identifying specific genetic alterations and biomarkers critical for determining treatment strategies. These diagnostics tools serve a crucial role by guiding targeted therapies, forecasting treatment outcomes, and enhancing patient responses. As the demand increases for personalized treatments that cater to individual patient needs, the importance of personalized medicine will also increase. Consequently, this surge in significance fuels the broader adoption and utilization of molecular targeted diagnostics across various healthcare settings worldwide. This symbiotic relationship between personalized medicine and molecular targeted diagnostics signifies a transformative shift toward more individualized and effective patient care strategies within the global healthcare landscape.

Increasing in Investments in Research & Development

Technological developments in diagnostic technologies are being driven by increased funding for research and development. These financial investments help develop more accurate, efficient, and widely available diagnostic tools. Additionally, they assist in validating and approving complicated diagnostic tests, broadening their usage across various healthcare domains. This increased funding substantially contributes to the market's expansion by improving diagnostic precision and effectiveness and, ultimately, fostering enhanced patient care on a larger scope. In August 2023, significant financial support was given to researchers at the City of Hope Medical Centre in California to develop a novel targeted chemotherapy. The new targeted chemotherapy showed promising results against all solid tumors in preclinical studies. Targeting proliferating cell nuclear antigen (PCNA), a protein that had been "undruggable," the novel drug candidate AOH1996 appears to eliminate all solid tumors related to PCNA.

Numerous Clinical Benefits of In Situ Hybridization

In situ hybridization (ISH) serves a critical function by allowing visualization and recognition of precise nucleic acid sequences within cells or tissues. This method assists in identifying gene expressions, changes, or disease-causing components, thereby aiding precise disease identification and tailored treatment approaches. As healthcare prioritizes targeted and personalized therapies more, the increased demand for precise molecular diagnostics, notably ISH, fosters the growth of global molecular targeted diagnostics market. This demand facilitates accurate identification and understanding of biomarkers, elevating diagnostic capacities across different diseases globally. In May 2023, Bio-Techne, revealed enhancements in advanced cell diagnostics (ACD)-branded RNAscope in situ hybridization (ISH) range. This extension involves the introduction of an RNAscope multiomic workflow designed for the Standard BioTools Hyperion Imaging System.

Government Initiatives

Governments actively participate in initiatives to enhance molecular targeted diagnostics by creating specialized research hubs. These initiatives are intended to progress research, foster innovation, and encourage the adoption of state-of-the-art diagnostic technologies. By nurturing environments conducive to research and development, these undertakings drive the growth and development of the global molecular targeted diagnostics market. These coordinated government initiatives stimulate technological progress and endorse the validation and assimilation of innovative diagnostic instruments, ultimately augmenting healthcare capabilities and advancing the quality of patient care globally. For instance, in August 2023, Kalyan Singh Super Specialty Cancer Institute (KSSSCI), a distinguished establishment operated by the Government of Uttar Pradesh, collaborated with Karkinos Healthcare and the Indian Institute of Technology Kanpur. This impactful three-way alliance signifies the launch of the 'Centre for Advanced Molecular Diagnostics and Research for Cancer (CAMDRC)', slated to be established in Lucknow.

Growing Demand for Infectious Disease Diagnostics

The rising demand for infectious disease diagnostics acts as a fundamental force propelling the global molecular targeted diagnostics market. This increase in demand arises from the essential need for precise, swift, and specialized diagnostic instruments to detect viruses, bacteria, or parasites accurately. Molecular targeted diagnostics is responsible for promptly identifying and characterizing these infectious agents, allowing for timely treatment choices and strategies to control infections. With persistent challenges posed by infectious diseases in the global healthcare scenario, the amplified necessity for accurate diagnostic tools drives the worldwide expansion and uptake of molecular targeted diagnostics. In April 2023, Thermo Fisher Scientific introduced the inaugural set of 37 CE-IVD-marked real-time PCR assay kits. Primarily designed for diagnosing infectious diseases, these kits are part of the company's plan to unveil a total of 37 such kits within the year. This launch signifies the introduction of Thermo Fisher Scientific's own company-branded test kits, enabling users of its QuantStudio Dx series of instruments to access a diverse range of testing options for the first time.

Outlook of Global Molecular Targeted Diagnostics Market

The future expansion prospects of the global molecular targeted diagnostics market are substantial. Technological advancements, especially in genomics, proteomics, and molecular biology, pave the path for more refined and thorough diagnostic tools. The rising prevalence of chronic illnesses, infectious diseases, and cancer cases on a global scale fuels the need for early detection and personalized therapies, fostering the adoption of molecular targeted diagnostics. Furthermore, the paradigm shifts toward personalized medicine, focusing on customized treatments rooted in individual genetic profiles, intensifies the demand for precise diagnostic methods. Ongoing investments in research and development by pharmaceutical and biotech firms aim to innovate and refine diagnostic precision. Government initiatives backing precision medicine and healthcare infrastructure also play pivotal roles in market growth. As healthcare professionals and patients become increasingly aware of the advantages of early diagnosis, the global molecular targeted diagnostics market is positioned for substantial expansion, leading to improved patient care and treatment outcomes worldwide.

Key Players Landscape and Outlook

Many companies in the global molecular targeted diagnostics market are actively participating in strategic partnerships. These alliances seek to merge knowledge, technologies, and resources to create advanced diagnostic tools. Collaborations facilitate the integration of various expertise and research capabilities, expediting the development of precise and efficient diagnostic solutions. Through leveraging collective strengths, companies navigate complexities, expanding market presence. These collaborations foster synergy, advancing the progress and acceptance of molecular targeted diagnostics. Consequently, they offer improved diagnostic accuracy and effectiveness, ultimately benefiting healthcare systems and global patients. In February 2023, Thermo Fisher Scientific disclosed that its Applied Biosystems TaqPath PCR kits used in diagnosing infectious diseases like multi-drug-resistant tuberculosis (MTB MDR), M. tuberculosis complex (MTB), hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and for genetic analysis (HLA B27) have obtained licensing approval from the Central Drugs Standard Control Organisation (CDSCO). Thermo Fisher Scientific will collaborate with Mylab Discovery Solutions to produce these kits in India.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Outlook of Global Molecular Targeted Diagnostics Market

4. Executive Summary

5. Global Molecular Targeted Diagnostics Market Outlook, 2017-2031F

  • 5.1. Market Size & Forecast
    • 5.1.1. Value
    • 5.1.2. Volume
  • 5.2. By Product
    • 5.2.1. Reagents & Kits
    • 5.2.2. Instruments
    • 5.2.3. Services & Software
  • 5.3. By Sample Type
    • 5.3.1. Blood, Serum, and Plasma
    • 5.3.2. Urine
    • 5.3.3. Others
  • 5.4. By Test Type
    • 5.4.1. Lab Tests
    • 5.4.2. PoC Tests
  • 5.5. By Technology
    • 5.5.1. Isothermal Nucleic Acid Amplification Technology
    • 5.5.2. DNA Sequencing & Next-generation Sequencing
    • 5.5.3. Polymerase Chain Reaction
    • 5.5.4. In Situ Hybridization
    • 5.5.5. DNA Microarrays
    • 5.5.6. Next Generation Sequencing
    • 5.5.7. Others
  • 5.6. By Application
    • 5.6.1. Infectious Disease Diagnostics
      • 5.6.1.1. Hepatitis
      • 5.6.1.2. HPV
      • 5.6.1.3. HIV
      • 5.6.1.4. HAI
      • 5.6.1.5. CT/NG
      • 5.6.1.6. Tuberculosis
      • 5.6.1.7. Influenza
      • 5.6.1.8. Others
    • 5.6.2. Oncology Testing
      • 5.6.2.1. Lung Cancer
      • 5.6.2.2. Prostate Cancer
      • 5.6.2.3. Breast Cancer
      • 5.6.2.4. Colorectal Cancer
      • 5.6.2.5. Others
    • 5.6.3. Genetic Testing
    • 5.6.4. Blood Testing
    • 5.6.5. Others
  • 5.7. By End-user
    • 5.7.1. Hospitals & Clinics
    • 5.7.2. Diagnostic Laboratories
    • 5.7.3. Others
  • 5.8. By Region
    • 5.8.1. North America
    • 5.8.2. Europe
    • 5.8.3. South America
    • 5.8.4. Asia-Pacific
    • 5.8.5. Middle East and Africa
  • 5.9. By Company Market Share (%), 2022

6. Global Molecular Targeted Diagnostics Market Outlook, By Region, 2017-2031F

  • 6.1. North America*
    • 6.1.1. By Product
      • 6.1.1.1. Reagents & Kits
      • 6.1.1.2. Instruments
      • 6.1.1.3. Services & Software
    • 6.1.2. By Sample Type
      • 6.1.2.1. Blood, Serum, and Plasma
      • 6.1.2.2. Urine
      • 6.1.2.3. Others
    • 6.1.3. By Test Type
      • 6.1.3.1. Lab Tests
      • 6.1.3.2. PoC Tests
    • 6.1.4. By Technology
      • 6.1.4.1. Isothermal Nucleic Acid Amplification Technology
      • 6.1.4.2. DNA Sequencing & Next-generation Sequencing
      • 6.1.4.3. Polymerase Chain Reaction
      • 6.1.4.4. In Situ Hybridization
      • 6.1.4.5. DNA Microarrays
      • 6.1.4.6. Next Generation Sequencing
      • 6.1.4.7. Others
    • 6.1.5. By Application
      • 6.1.5.1. Infectious Disease Diagnostics
      • 6.1.5.1.1. Hepatitis
      • 6.1.5.1.2. HPV
      • 6.1.5.1.3. HIV
      • 6.1.5.1.4. HAI
      • 6.1.5.1.5. CT/NG
      • 6.1.5.1.6. Tuberculosis
      • 6.1.5.1.7. Influenza
      • 6.1.5.1.8. Others
      • 6.1.5.2. Oncology Testing
      • 6.1.5.2.1. Lung Cancer
      • 6.1.5.2.2. Prostate Cancer
      • 6.1.5.2.3. Breast Cancer
      • 6.1.5.2.4. Colorectal Cancer
      • 6.1.5.2.5. Others
      • 6.1.5.3. Genetic Testing
      • 6.1.5.4. Blood Testing
      • 6.1.5.5. Others
    • 6.1.6. By End-user
      • 6.1.6.1. Hospitals & Clinics
      • 6.1.6.2. Diagnostic Laboratories
      • 6.1.6.3. Others
    • 6.1.7. United States*
      • 6.1.7.1. By Product
      • 6.1.7.1.1. Reagents & Kits
      • 6.1.7.1.2. Instruments
      • 6.1.7.1.3. Services & Software
      • 6.1.7.2. By Sample Type
      • 6.1.7.2.1. Blood, Serum, and Plasma
      • 6.1.7.2.2. Urine
      • 6.1.7.2.3. Others
      • 6.1.7.3. By Test Type
      • 6.1.7.3.1. Lab Tests
      • 6.1.7.3.2. PoC Tests
      • 6.1.7.4. By Technology
      • 6.1.7.4.1. Isothermal Nucleic Acid Amplification Technology
      • 6.1.7.4.2. DNA Sequencing & Next-generation Sequencing
      • 6.1.7.4.3. Polymerase Chain Reaction
      • 6.1.7.4.4. In Situ Hybridization
      • 6.1.7.4.5. DNA Microarrays
      • 6.1.7.4.6. Next Generation Sequencing
      • 6.1.7.4.7. Others
      • 6.1.7.5. By Application
      • 6.1.7.5.1. Infectious Disease Diagnostics
      • 6.1.7.5.1.1. Hepatitis
      • 6.1.7.5.1.2. HPV
      • 6.1.7.5.1.3. HIV
      • 6.1.7.5.1.4. HAI
      • 6.1.7.5.1.5. CT/NG
      • 6.1.7.5.1.6. Tuberculosis
      • 6.1.7.5.1.7. Influenza
      • 6.1.7.5.1.8. Others
      • 6.1.7.5.2. Oncology Testing
      • 6.1.7.5.2.1. Lung Cancer
      • 6.1.7.5.2.2. Prostate Cancer
      • 6.1.7.5.2.3. Breast Cancer
      • 6.1.7.5.2.4. Colorectal Cancer
      • 6.1.7.5.2.5. Others
      • 6.1.7.5.3. Genetic Testing
      • 6.1.7.5.4. Others
      • 6.1.7.6. By End-user
      • 6.1.7.6.1.1. Hospital & Clinics
      • 6.1.7.6.1.2. Diagnostic Laboratories
      • 6.1.7.6.1.3. Others
      • 6.1.7.7. Canada
      • 6.1.7.8. Mexico

All segments will be provided for all regions and countries covered:

  • 6.2. Europe
    • 6.2.1 Germany
    • 6.2.2 France
    • 6.2.3 Italy
    • 6.2.4 United Kingdom
    • 6.2.5 Russia
    • 6.2.6 Netherlands
    • 6.2.7 Spain
    • 6.2.8 Turkey
    • 6.2.9 Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
  • 6.4. Asia-Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2023

  • 7.1. By Product
  • 7.2. By Sample Type
  • 7.3. By Test Type
  • 7.4. By Technology
  • 7.5. By Application
  • 7.6. By End-user
  • 7.7. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis
  • 8.3. Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges and Restraints)

10. Regulatory Framework and Innovation

  • 10.1 Clinical Trials
  • 10.2 Patent Landscape
  • 10.3 Regulatory Approvals
  • 10.4 Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. F. Hoffmann-La Roche Ltd.
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. Novartis AG
  • 14.3. Abbott Laboratories
  • 14.4. Becton, Dickinson, and Company
  • 14.5. Siemens Healthineers
  • 14.6. Agilent Technologies, Inc.
  • 14.7. Hologic, Inc.
  • 14.8. bioMerieux SA
  • 14.9. QIAGEN Biotechnology Malaysia Sdn Bhd.
  • 14.10. Danaher Corporation
  • 14.11. Illumina, Inc.
  • 14.12. Thermo Fisher Scientific Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제